Establishment Labs (NASDAQ:ESTA – Get Free Report) and Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk.
Valuation and Earnings
This table compares Establishment Labs and Vivos Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Establishment Labs | $211.08 million | 10.03 | -$51.06 million | ($1.31) | -54.23 |
| Vivos Therapeutics | $17.44 million | 0.13 | -$21.17 million | ($1.90) | -0.08 |
Profitability
This table compares Establishment Labs and Vivos Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Establishment Labs | -15.82% | -196.69% | -10.73% |
| Vivos Therapeutics | -122.00% | -2,325.64% | -102.01% |
Insider and Institutional Ownership
72.9% of Establishment Labs shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 10.0% of Establishment Labs shares are owned by company insiders. Comparatively, 2.1% of Vivos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
Establishment Labs has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 6.04, meaning that its share price is 504% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Establishment Labs and Vivos Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Establishment Labs | 1 | 0 | 8 | 0 | 2.78 |
| Vivos Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
Establishment Labs presently has a consensus target price of $100.25, indicating a potential upside of 41.10%. Vivos Therapeutics has a consensus target price of $2.80, indicating a potential upside of 1,639.13%. Given Vivos Therapeutics’ higher possible upside, analysts clearly believe Vivos Therapeutics is more favorable than Establishment Labs.
Summary
Establishment Labs beats Vivos Therapeutics on 10 of the 14 factors compared between the two stocks.
About Establishment Labs
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
About Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.
